For years, the Breast Cancer Fund has advocated to eliminate BPA (in hard plastics and can linings) and parabens (in cosmetics) from consumer products because of their links to breast cancer risk. Now we have new evidence that BPA and methylparaben not only spur normal human breast cells to behave like cancer cells, they also resist the cancer-inhibiting effects of the drug tamoxifen.
Our CEO Jeanne Rizzo spoke to the San Francisco Chronicle about this new research from California Pacific Medical Center:
Jeanne Rizzo, chief executive officer of the Breast Cancer Fund, a San Francisco advocacy group, said the study shows that BPA and methylparaben have a triggering effect when it comes to cancer. The next step, she said, has to be for consumers to demand changes that reduce environmental exposure to these chemicals.
A bill sitting on the governor's desk would ban BPA in sippy cups and baby bottles manufactured or sold in California. AB1319 was authored by Assemblywoman Betsy Butler, D-Los Angeles.
This research is sharp warning to consumer, legislators, manufacturers and researchers alike. As the Chronicle article explains:
Since most breast cancers are driven by the hormone estrogen, the bulk of the drugs used to treat breast cancer are designed to knock down estrogen. BPA and methylparaben not only mimic estrogen's ability to drive cancer, but appear to be even better than the natural hormone in bypassing the ability of drugs to treat it, [lead researcher Dr. William] Goodson said. (Read complete article.)